Healthcare
Revelation Biosciences, Inc.(REVB)
Live Price
Offline$0.98
-8.41% today
1Y Change
-88.05%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +72.7%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Revelation Biosciences, Inc. (REVB) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.98 and down 88.0% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +72.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +72.7%, free cash flow +54.9% with operating margin 0.0% and ROIC -94.4%. Stock Foundry combines REVB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +72.7%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -5.0% | +4.9% | -3.3% |
2026 Feb 26, 2026 | +54.9% | -0.8% | -6.8% | -15.0% |
2025 Nov 6, 2025 | -32.1% | -2.9% | -9.7% | +2.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REVB
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
REVB Max Drawdown
-92.23%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for REVB and SPY.
Company Overview
Revelation Biosciences, Inc.
NASDAQ Capital Market
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
- Leadership
- James Rolke
- IPO Date
- Nov 17, 2020
- Employees
- 8
- Street Address
- 4660 La Jolla Village Drive
- Mailing
- San Diego, CA, 92122
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 800 3717
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.6
- Price/Sales
- โ
- Price/Book
- 0.1
Growth
- Revenue
- 0.0%
- EPS
- +72.7%
- Free Cash Flow
- +54.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -134.2%
- ROIC
- -94.4%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 5.41
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.